TUESDAY, Sept. 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Inluriyo (imlunestrant), an oral estrogen receptor antagonist, for the treatment of adults with estrogen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback